Press Releases :: Sonnet BioTherapeutics, Inc. (PURR)

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Trading on The Nasdaq Capital Market under the ticker symbol “PURR”

Full Press Release Here

May 17, 2021 7:00am EDT

Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update

May 10, 2021 6:30am EDT

Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)

May 03, 2021 6:00am EDT

Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics

Mar 29, 2021 4:30pm EDT

Sonnet BioTherapeutics Provides 2021 Business Update

Mar 22, 2021 7:00am EDT

Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations

Feb 16, 2021 8:10am EST

Sonnet BioTherapeutics Provides Fiscal Year 2021 First Quarter Business and Earnings Update

Feb 03, 2021 6:30am EST

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021 Annual Meeting

Feb 01, 2021 6:30am EST

Sonnet BioTherapeutics Completes Successful Repeat Dose Study of SON-1010 in Non-Human Primates

Jan 25, 2021 6:30am EST

Sonnet BioTherapeutics Announces the Successful Completion of a Non-human Primate Toxicology Study of SON-080

Dec 17, 2020 6:30am EST

Sonnet BioTherapeutics Provides Fiscal Year 2020 Business and Earnings Update

1...
4
5
6
7
8
9
10
11
12
13